De Novo

• Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S, 566 U.S. (2012)

(Slip Opinion) OCTOBER TERM, 2011 NOTE: Where it is feasible, a syllabus (headnote) will be released, as isbeing done in connection with this case, at...

• U.S. Supreme Court

• Novo Nordisk Awards $1.5 Million Grant

This project will be the first large consortium study to determine how diabetes is treated in children and youth with type 1 diabetes at leading pediatric diabetes centers in the United States," said Dr. [Roy W. Beck, M.D.]. "The consortium also will provide updated information regarding rates of severe hypoglycemia, serious adverse events, as well as evidence to direct future care and research. "The Pediatric Diabetes Consortium is an important step in changing diabetes for people, specifically children, with type 1 diabetes," said Dr. Nathaniel Clark, senior medical advisor for diabetes at Novo Nordisk. "It will take the combined and shared knowledge of the health care community to improve the treatment of those with diabetes and ultimately to defeat the disease. The registry is a b...

• Sentinel; Los Angeles, Calif.
• September 07, 2009

• 12 CFR 543.3 - “De novo” applications for a Federal savings association charter.

• Code of Federal Regulations - Title 12: Banks and Banking

• Section 146 Establishes De Novo Review

This article previously appeared in Last Month at the Federal Circuit November, 2011. Judges:  Newman (author), O'Malley, Reyna [Appealed from ...

• Mondaq Business Briefing
• United States Law Articles in English

• 12 CFR 1263.14 - De novo insured depository institution applicants.

• Code of Federal Regulations - Title 12: Banks and Banking

• Bgi Releases a Complete de Novo E. Available to Worldwide Disease Control and Research Agencies

CAMBRIDGE, Mass. and SHENZHEN, China, June 7, 2011 /PRNewswire/ - - Scientists worldwide have been working on the publicly available genomic sequences of the deadly E. coli O104 strain, which is causing the current health crisis in Germany and now spreading throughout Europe. To continue to speed the ongoing international efforts of researchers to assess and halt this growing epidemic, BGI and their collaborators at the University Medical Centre Hamburg- Eppendorf have now released their third version of the assembled genome, which includes new data from this E. coli O104. (ftp:// ftp.genomics.org.cn/pub/Ecoli_TY-2482/Escherichia_coli_TY- 2482.contig.20110606.fa.gz). In addition, the FTP site contains a file that provides the PCR primer sequences BGI and its collaborators have used to c...

• U.S. Newswire
• June 07, 2011

• 20 CFR 655.1315 - Administrative review and de novo hearing before an administrative law judge.

• Code of Federal Regulations - Title 20: Employees' Benefits

• Guidance for Industry and Food and Drug Administration Staff; Factors To Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and de Novo Classifications; Availability

The Food and Drug Administration (FDA) is announcing the availability of the guidance document entitled ``Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications.'' This guidance is intended to provide greater clarity on FDA's decisionmaking process with regard to benefit-risk determinations in the premarket review of medical devices in the premarket approval and de novo pathways.

• Federal Register Nbr. 77 FR 18828, March 28, 2012
• Notices
• Health and Human Services Department

• Secrets of de Novo Success

Frank Sorrentino, a real estate developer in northern New Jersey, was having a hard time finding the kind of customer service he was used to. His local community bank had been acquired by a larger institution - then bought again by an even bigger organization. Gone was the local touch and feel of a bank where he once knew everyone. But instead of getting mad, Sorrentino got even - he formed his own financial institution. Sorrentino recruited an organizing group, raised capital, and received a state charter in just five months - an unusually short time period for a de novo. North Jersey Community Bank, based in Englewood Cliffs, opened its doors in February 2005 and Sorrentino has not looked back. By the end of last year, the bank had amassed $180 million in assets and become profitable;...

• Bank Director
• Vol. 17 Nbr. 2, April 2007

• Vivian Garriga v. Novo Nordisk, Inc., (11th Cir. 2010)

[DO NOT PUBLISH] IN THE UNITED STATES COURT OF APPEALS FO...

• Federal Circuits